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The Authors Reply: We thank Drs Komaba and Fukagawa
for their remarks1 and for giving us the opportunity to add to
our review2 some comments on amino-parathyroid hormone
(N-PTH). Determining the exact nature of N-PTH and
understanding its regulation and action(s) is an exciting but
challenging ﬁeld for future research. Although a very
excessive production of N-PTH can be easily evidenced by
the ﬁnding of a third/second-generation PTH ratio 41, we
would like to underline an important technical point. As
several automated third-generation assays will become
available soon, it is likely that many studies will focus on
the third/second-generation PTH ratio. However, this ratio
cannot be calculated from any coupling of PTH assays
(one third-generation and one second-generation assay).
Indeed, both assays must be calibrated similarly (i.e., must
produce the same concentration in a solution of rh1–84 PTH),
and the second-generation assay must measure both 7–84 and
1–84 PTH with 100% cross-reactivity, but must not measure
N-PTH. To our knowledge, this could currently be achieved
only with the Ti-PTH assay (second-generation) and the
CA-PTH assay (third-generation) from Scantibodies Labora-
tories (Santee, CA, USA). Nevertheless, a third/second-
generation PTH ratio 41 is a very rare feature,3 and the
best way to improve our knowledge in N-PTH physiology
would be to develop a simple and direct N-PTH assay.
Indeed, the only published method is complicated and
reserved to highly specialized research laboratories.4 Having
said that, the ﬁnding by Drs Komaba and Fukagawa of the
normalization of a reversed ratio during calcimimetic therapy
is striking and deserves further study.5
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Statins: do we definitely know
whether they are completely
inefficacious in ESRD?
To the Editor: We wish to submit a letter concerning the
paper by Lam et al. in Kidney International.1 Although the
data are certainly of interest, we feel that some note of caution
will put the argument of the authors into a slightly different
perspective.
The paper of Lam et al.1 reports that prescription of statins
in dialysis patients continued unchanged despite the negative
outcome in hemodialyzed patients of one study (4D; Wanner
et al.,2 and in the meantime even in a second one: AURORA3).
The observation is certainly of interest, but we wish to
raise a note of caution regarding the interpretation of the
evidence for the inefﬁcacy of statins.
In the past, it had appeared a priori pathogenetically
plausible that lipid lowering in uremic patients should reduce
cardiac events. That pathophysiological plausibility does
not necessarily translate into evidence-based outcomes of
adequately powered prospective intervention trials has
recently been impressively shown by the TREAT study on
erythropoietin treatment.4
The issue we wish to raise here is the absolute requirement
that studies must be adequately powered before the conclusion
is drawn that a given treatment is ineffective. Indeed both the
4D and the AURORA study were underpowered to provide
biostatistical proof for the efﬁcacy of statins on myocardial
infarction. In both studies the primary outcome was a
composite comprising sudden death and death from other
cardiac causes, including myocardial infraction and stroke.
When planning the studies it was assumed that lipid lowering
by statins would reduce such a combined cardiac and
cerebrovascular end point. Post hoc we noted that statins had
deﬁnitely no signiﬁcant effect with respect to sudden death and
heart failure. However, as we had pointed out elsewhere,5 the
study was presumably underpowered to exclude efﬁcacy for all
types of cardiac death. The post hoc analysis even pointed to a
suggestive beneﬁt for adjudicated coronary end points that
were lower by 19% per 1mmol lowering of low-density
lipoprotein-cholesterol—surprisingly identical with what had
been observed previously in studies on nonrenal cardiac
patients.6
It is also remarkable that both in 4D and the AURORA
study, a trend was seen for separation of the survival curves
approximately 3 years after start of the study—in stark
contrast to the almost immediate effect of statins seen in
nonrenal patients with coronary heart disease. It is possible
that in hemodialyzed patients statins don’t affect inveterate
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